The implications of heterogeneous DNA methylation for the accurate quantification of methylation

被引:101
作者
Mikeska, Thomas [1 ,2 ]
Candiloro, Ida L. M. [1 ,2 ]
Dobrovic, Alexander [1 ,2 ]
机构
[1] Peter MacCallum Canc Ctr, Dept Pathol, Mol Pathol Res & Dev Lab, Melbourne, Vic 8006, Australia
[2] Univ Melbourne, Melbourne, Vic 3010, Australia
关键词
biomarker; cancer; CDKN2B; digital PCR; high-resolution melting; MGMT; minimal residual disease; molecular diagnostics; NUCLEOTIDE PRIMER EXTENSION; MGMT PROMOTER METHYLATION; CPG ISLAND METHYLATION; POLYMERASE-CHAIN-REACTION; HIGH-THROUGHPUT; PCR BIAS; EPIGENETIC BIOMARKER; CYTOSINE-METHYLATION; GENE; CANCER;
D O I
10.2217/EPI.10.32
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
DNA methylation based biomarkers have considerable potential for molecular diagnostics, both as tumor specific biomarkers for the early detection or post-therapeutic monitoring of cancer as well as prognostic and predictive biomarkers for therapeutic stratification. Particularly in the former, the accurate estimation of DNA methylation is of compelling importance. However, quantification of DNA methylation has many traps for the unwary, especially when heterogeneous methylation comprising multiple alleles with varied DNA methylation patterns (epialleles) is present. The frequent occurrence of heterogeneous methylation as distinct from a simple mixture of fully methylated and unmethylated alleles is generally not taken into account when DNA methylation is considered as a cancer biomarker. When heterogeneous DNA methylation is present, the proportion of methylated molecules is difficult to quantify without a method that allows the measurement of individual epialleles. In this article, we critically assess the methodologies frequently used to investigate DNA methylation, with an emphasis on the detection and measurement of heterogeneous DNA methylation. The adoption of digital approaches will enable the effective use of heterogeneous DNA methylation as a cancer biomarker.
引用
收藏
页码:561 / 573
页数:13
相关论文
共 88 条
[1]   DAP-kinase CpG island methylation in acute myeloid leukemia: methodology versus biology? [J].
Aggerholm, A ;
Hokland, P ;
Guldberg, P .
BLOOD, 2000, 95 (09) :2997-2998
[2]  
Aggerholm A, 1999, CANCER RES, V59, P436
[3]  
Ahuja N, 1998, CANCER RES, V58, P5489
[4]  
BARELI M, 1989, BLOOD, V73, P281
[5]  
Baumer A, 2001, HUM MUTAT, V17, P423, DOI 10.1002/humu.1118
[6]  
Bianco T, 1999, HUM MUTAT, V14, P289, DOI 10.1002/(SICI)1098-1004(199910)14:4<289::AID-HUMU3>3.0.CO
[7]  
2-A
[8]   BiQ analyzer: visualization and quality control for DNA methylation data from bisulfite sequencing [J].
Bock, C ;
Reither, S ;
Mikeska, T ;
Paulsen, M ;
Walter, J ;
Lengauer, T .
BIOINFORMATICS, 2005, 21 (21) :4067-4068
[9]   Epigenetic biomarker development [J].
Bock, Christoph .
EPIGENOMICS, 2009, 1 (01) :99-110
[10]   Quantitative high-resolution CpG island mapping with Pyrosequencing™ reveals disease-specific methylation patterns of the CDKN2B gene in Myelodysplastic syndrome and myeloid leukemia [J].
Brakensiek, Kai ;
Wingen, Luzie U. ;
Langer, Florian ;
Kreipe, Hans ;
Lehmann, Ulrich .
CLINICAL CHEMISTRY, 2007, 53 (01) :17-23